Aligos Therapeutics, Inc.ALGSNASDAQ
Loading
R&D Expenses Over TimeStable
Percentile Rank29
3Y CAGR-6.5%
5Y CAGR-2.8%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
-6.5%/yr
vs +68.9%/yr prior
5Y CAGR
-2.8%/yr
Recent deceleration
Acceleration
-75.4pp
Decelerating
Percentile
P29
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
4 yr
Consecutive declineStable
PeriodValueYoY Change
2025$69.45M-1.2%
2024$70.27M-3.8%
2023$73.04M-14.1%
2022$85.08M-18.3%
2021$104.15M+30.4%
2020$79.89M+81.4%
2019$44.04M+321.2%
2018$10.46M-